Cataplexy — the sudden, involuntary loss of muscle tone triggered by strong emotion — is one of the most disruptive and least treatable symptoms of narcolepsy, capable of causing a person to collapse mid-laugh or mid-argument with no warning. A drug now under FDA review posted some of the fastest symptom relief reported in a cataplexy trial to date.
The FDA has accepted for filing Axsome Therapeutics' New Drug Application for AXS-12 (reboxetine) as a treatment for cataplexy associated with narcolepsy, the company announced. The agency has set a Prescription Drug User Fee Act target action date of May 1, 2027, and does not currently plan to convene an advisory committee to review the application.
An Old Drug Repurposed for a Narrow, Disabling Symptom
AXS-12 is built around reboxetine, a norepinephrine reuptake inhibitor that has been used in other countries for depression for years but was never approved in the United States. Axsome is developing it specifically for cataplexy, working through its effects as a norepinephrine reuptake inhibitor and cortical dopamine modulator — mechanisms believed to help stabilize the neural circuits that lose control of muscle tone during cataplexy episodes.
Cataplexy affects most people with narcolepsy type 1 and can range from a brief buckling of the knees to a full-body collapse lasting several minutes, all while the person typically remains conscious. Episodes are frequently triggered by laughter, surprise, or anger, forcing many patients to suppress normal emotional responses to avoid an attack — a burden that extends well beyond the physical symptom itself.
Rapid, Sizable Reductions in Attacks
The NDA is supported by data from two phase 3 trials, SYMPHONY and ENCORE. In SYMPHONY, patients taking AXS-12 saw weekly cataplexy attacks drop by 56% within the first week of treatment, compared with a 31% reduction in the placebo group — a gap that appeared almost immediately rather than building gradually over weeks, as is typical with many neurological and psychiatric medications.
Longer-term data from ENCORE showed continued improvements in overall narcolepsy status beyond cataplexy frequency alone, including gains in functional outcomes and cognition, suggesting the drug's benefits may extend to the broader daily impact of narcolepsy rather than a single symptom in isolation. The most commonly reported side effects in the SYMPHONY trial were dry mouth, nausea, and constipation.
Filling a Narrow but Real Treatment Gap
Current options for cataplexy include sodium oxybate formulations, which require nighttime dosing and carry their own tolerability and access challenges, and certain antidepressants used off-label for their anticataplectic effects, including venlafaxine and other norepinephrine- or serotonin-acting drugs. AXS-12 would be among the few medications developed and formally tested specifically for cataplexy rather than adapted from other indications.
The drug has received FDA Orphan Drug Designation, a status granted to treatments for rare diseases that typically comes with development incentives including extended market exclusivity. Narcolepsy type 1, the form of the condition most closely tied to cataplexy, is estimated to affect roughly 1 in 2,000 people in the U.S., a small enough population that dedicated drug development has historically lagged behind more common sleep disorders.
Part of a Broader Push in Narcolepsy Drug Development
AXS-12's review comes amid a wider wave of investment in narcolepsy treatment. Orexin receptor agonists, a newer drug class that targets the neurotransmitter system destroyed in narcolepsy type 1, have drawn major pharmaceutical investment in the past year, including large acquisitions aimed at bringing orexin-based therapies to market. AXS-12 takes a different mechanistic approach, targeting cataplexy specifically rather than the broader orexin deficiency underlying the disease, positioning it as a potential complement to — rather than competitor with — that emerging drug class.
What This Means for Patients
An FDA filing acceptance is not an approval — the agency's review will take months, and the May 2027 target date could shift. Patients with narcolepsy and cataplexy should not expect access to AXS-12 in the near term, and existing treatments remain the standard of care in the meantime.
But for a symptom that has had few dedicated treatment options and can be socially and physically limiting enough to make patients avoid situations that trigger strong emotion, a drug with rapid, substantial effects in late-stage trials represents a meaningful addition to the pipeline. Patients interested in the trial data or considering whether to discuss emerging options with their sleep specialist can find additional detail in Axsome's trial disclosures as the FDA review proceeds.
